Onyema E. Ogbuagu, MBBCh, FIDSA, is Associate Professor of Medicine and Director of the Antivirals and Vaccines Research Program at Yale School of Medicine in New Haven, Connecticut. He is also Attending Physician of Infectious Diseases at Yale-New Haven Health.
Dr. Ogbuagu received his medical degree (MBBCh) from the University of Calabar in Calabar, Nigeria. He then completed his residency at Mount Sinai School of Medicine in New York, followed by a fellowship at Yale School of Medicine in New Haven, Connecticut.
In the clinical setting, Dr. Ogbuagu is involved with educating and training medical students, residents, and infectious disease fellows in various capacities in the inpatient and outpatient settings. Through an award from the National Academy of Sciences/US Agency for International Development, he trained Liberia's first-ever Infectious Diseases physician who achieved fellowship of the West African College of Physicians in that specialty in 2022.
Dr. Ogbuagu has served as the principal investigator (PI) on numerous pharmacokinetic, Phase 2 and 3 safety and efficacy trials of novel antiviral compounds for both HIV and SARS CoV-2. He was a lead investigator on the international DISCOVER trial evaluating tenofovir alafenamide and emtricitabine (TAF/FTC) versus tenofovir disoproxil fumarate and emtricitabine (TDF/FTC) for HIV prevention among MSM and transgender women, as well as the PURPOSE-2 trial evaluating long-acting lenacapavir for pre-exposure prophylaxis (PrEP) among men who have sex with men, transgender women, transgender men, and gender nonbinary individuals.
In response to the COVID-19 pandemic, Dr. Ogbuagu served as the Yale PI on multiple investigational therapeutic and preventative clinical trials, including remdesivir (now FDA-approved), leronlimab, and remdesivir and tocilizumab combination therapy, as well as the Pfizer/BioNTech and GSK/Sanofi COVID-19 vaccine trials. He is also the PI for ongoing trials evaluating mRNA vaccines for other infectious diseases and vaccines for bacterial infection.